Effect of a rescue or recurrence dose of lasmiditan on efficacy and safety in the acute treatment of migraine: findings from the phase 3 trials (SAMURAI and SPARTAN)

Table 1 Second dose study populations

FIRST DOSE →	Placebo (N = 1262)	Lasmiditan 50 mg (N = 654)	Lasmiditan 100 mg (N = 1265)	Lasmiditan 200 mg (N = 1258)
Intention-to-treat population,^a n	1130	598	1133	1120
Pain at 2 h, n (%)^b,c	924 (82%)	429 (72%)	796 (70%)	724 (65%)
Took rescue dose, n (%)^d	606 (66%)	245 (57%)	388 (49%)	310 (43%)
Pain free at 2 h, n (%)^b	206 (18%)	169 (28%)	337 (30%)	396 (35%)
Took recurrence dose, n (%)^e	21 (10%)	13 (8%)	35 (10%)	28 (7%)

^aTook first dose of study drug and had any post-dose headache severity or symptom assessments
^bDenominator = first dose ITT population
^cAlso included patients with missing data, who were assumed not to be pain free at 2 h
^dDenominator = pain at 2 h population
^eDenominator = pain free at 2 h population

ISSN: 1471-2377